Enzene Biosciences has raised $50million to expand in its core market of India and US.


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Enzene Biosciences has raised $ 50 million to improve its manufacturing capability in order to provide affordable, high-quality medicines that save lives.

Enzene Biosciences has raised $50 million (approximately 408 crore) in fresh equity funding from Eight Road ventures and healthcare investor F-Prime Capital. . Alkem Laboratories has also invested in the fresh round.

Enzene Biosciences is a Biotech company, a subsidiary of Mumbai-based drug maker Alkem Laboratories. They have invested in technologies of the future that allow accelerated development of your products. Pune-based Enzene focuses on producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals.  Enzene intends to establish a production and research & development facility in the US.

In a press statement, Enzene said it would leverage the fresh funds to enhance its manufacturing capabilities and drive expansion in its core market of India and the US.

“We have been tracking the broader biologics segment in India for several years, seeking disruptive technologies, products and management teams. Companies like Enzene position India well at the forefront of global biotech innovation,” said Prem Pavoor, senior partner, head of India and healthcare investments, Eight Roads Ventures.

Eight Roads, is backed by US financial services Fidelity has supported companies including Whatfix, Icertis, and Pharmeasy, a company for an online pharmacy.

“Internationally, the US and Europe remain key markets for Enzene with the aim of expanding into new geographies in their mission to become the most sought after CDMO (contract development & manufacturing organization),” said Ketan Patel, partner at F-Prime Capital.

In India, F-Prime has invested in companies like medtech startup Core Diagnostics, therapeutics venture Immuneel and Pharmeasy.

Tags : #fundingalert #Enzene #enzenebiosciences #biotechcompany #biotechnology #science #eightroads #f-prime #smitakumar #medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026